Literature DB >> 20935028

Increasing incidence of multiple sclerosis in women in Northern Finland.

O Krökki1, R Bloigu, M Reunanen, A M Remes.   

Abstract

BACKGROUND: The geographical distribution of multiple sclerosis (MS) means that prevalence rates increase with latitude north or south of the equator. Temporally, a tendency for increased incidences of MS has been observed over the past two decades.
OBJECTIVES: Since epidemiological studies of MS in areas close to the Arctic Circle are rare, we evaluated the incidence and prevalence of MS in Northern Ostrobothnia by means of a retrospective cohort study covering the period 1992-2007.
METHODS: Patients with a definite clinical diagnosis of MS based on the Poser criteria and the early McDonald criteria of 2001 were identified in the region of Northern Ostrobothnia (population 386,972) and the incidence was calculated at 1-year time intervals, both overall and by gender.
RESULTS: The overall prevalence was 103/100,000 (95% CI, 93-113), with a female/male ratio of 2.17. The mean overall incidence was 6.3/100,000 (95% CI, 5.2-7.2). The incidence shows a tendency to increase over the 16-year period due to a pronounced rise in the female incidence.
CONCLUSIONS: Our results show a high prevalence of MS in Northern Ostrobothnia and a disproportional increase in the female MS incidence. These recent epidemiological features may be associated with environmental risk factors such as a vitamin D deficit, low life-long UV radiation and the high-latitude geographical location.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20935028     DOI: 10.1177/1352458510384012

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  8 in total

1.  XVI European Charcot Foundation lecture: nutrition and environment: can MS be prevented?

Authors:  Kelly Claire Simon; Kassandra L Munger; Alberto Ascherio
Journal:  J Neurol Sci       Date:  2011-10-04       Impact factor: 3.181

2.  Incidence of multiple sclerosis among European Economic Area populations, 1985-2009: the framework for monitoring.

Authors:  Enrique Alcalde-Cabero; Javier Almazán-Isla; Antonio García-Merino; Joao de Sá; Jesús de Pedro-Cuesta
Journal:  BMC Neurol       Date:  2013-06-12       Impact factor: 2.474

3.  High nationwide incidence of multiple sclerosis in Sweden.

Authors:  Cecilia Ahlgren; Anders Odén; Jan Lycke
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

4.  Epidemiology of Guillain-Barré syndrome in Finland 2004-2014.

Authors:  Jussi O T Sipilä; Merja Soilu-Hänninen; Jori O Ruuskanen; Päivi Rautava; Ville Kytö
Journal:  J Peripher Nerv Syst       Date:  2017-11-15       Impact factor: 3.494

5.  A Systematic Assessment of Prevalence, Incidence and Regional Distribution of Multiple Sclerosis in Bavaria From 2006 to 2015.

Authors:  Tanja Daltrozzo; Alexander Hapfelmeier; Ewan Donnachie; Antonius Schneider; Bernhard Hemmer
Journal:  Front Neurol       Date:  2018-10-30       Impact factor: 4.003

6.  Incidence and prevalence of multiple sclerosis in Hungary based on record linkage of nationwide multiple healthcare administrative data.

Authors:  Anna Iljicsov; Dániel Milanovich; András Ajtay; Ferenc Oberfrank; Mónika Bálint; Balázs Dobi; Dániel Bereczki; Magdolna Simó
Journal:  PLoS One       Date:  2020-07-27       Impact factor: 3.240

Review 7.  The incidence and prevalence, diagnosis, and treatment of multiple sclerosis in China: a narrative review.

Authors:  Dongmei Jia; Yu Zhang; Chunsheng Yang
Journal:  Neurol Sci       Date:  2022-05-18       Impact factor: 3.830

8.  The DNA copy number of human endogenous retrovirus-W (MSRV-type) is increased in multiple sclerosis patients and is influenced by gender and disease severity.

Authors:  Marta Garcia-Montojo; María Dominguez-Mozo; Ana Arias-Leal; Ángel Garcia-Martinez; Virginia De las Heras; Ignacio Casanova; Raphaël Faucard; Nadège Gehin; Alexandra Madeira; Rafael Arroyo; François Curtin; Roberto Alvarez-Lafuente; Hervé Perron
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.